KR20160124569A - Liquid phase composition for smoking habit helping apparatus - Google Patents
Liquid phase composition for smoking habit helping apparatus Download PDFInfo
- Publication number
- KR20160124569A KR20160124569A KR1020150055413A KR20150055413A KR20160124569A KR 20160124569 A KR20160124569 A KR 20160124569A KR 1020150055413 A KR1020150055413 A KR 1020150055413A KR 20150055413 A KR20150055413 A KR 20150055413A KR 20160124569 A KR20160124569 A KR 20160124569A
- Authority
- KR
- South Korea
- Prior art keywords
- parts
- weight
- vitamin
- liquid composition
- smoking habit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000000391 smoking effect Effects 0.000 title claims abstract description 30
- 239000007791 liquid phase Substances 0.000 title description 5
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 239000000796 flavoring agent Substances 0.000 claims abstract description 16
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 16
- 239000002904 solvent Substances 0.000 claims abstract description 11
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 8
- 239000003205 fragrance Substances 0.000 claims abstract description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- DBZAKQWXICEWNW-UHFFFAOYSA-N 2-acetylpyrazine Chemical compound CC(=O)C1=CN=CC=N1 DBZAKQWXICEWNW-UHFFFAOYSA-N 0.000 claims description 10
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 244000246386 Mentha pulegium Species 0.000 claims description 6
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 6
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 6
- 229930003270 Vitamin B Natural products 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 235000001050 hortel pimenta Nutrition 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- IAEGWXHKWJGQAZ-UHFFFAOYSA-N trimethylpyrazine Chemical compound CC1=CN=C(C)C(C)=N1 IAEGWXHKWJGQAZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000019156 vitamin B Nutrition 0.000 claims description 6
- 239000011720 vitamin B Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002304 perfume Substances 0.000 claims description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 3
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical group CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 claims description 3
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 3
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 claims description 3
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 claims description 3
- 229940093503 ethyl maltol Drugs 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract description 9
- 229960002715 nicotine Drugs 0.000 abstract description 9
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract description 9
- 239000003607 modifier Substances 0.000 abstract description 8
- 239000003183 carcinogenic agent Substances 0.000 abstract description 6
- 210000003928 nasal cavity Anatomy 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 231100000357 carcinogen Toxicity 0.000 abstract description 4
- 239000003571 electronic cigarette Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 206010006326 Breath odour Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001683 mentha spicata herb oil Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 235000019721 spearmint oil Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006200 vaporizer Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 241000533293 Sesbania emerus Species 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- PMTBZAVERRPRHU-YGVNLFKFSA-N CC1(C)CCCC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C.CC1(C)CCCC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C Chemical compound CC1(C)CCCC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C.CC1(C)CCCC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C PMTBZAVERRPRHU-YGVNLFKFSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229940124535 smoking cessation aid Drugs 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D1/00—Cigars; Cigarettes
- A24D1/14—Tobacco cartridges for pipes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D1/00—Cigars; Cigarettes
- A24D1/18—Selection of materials, other than tobacco, suitable for smoking
-
- A24F47/008—
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 전자담배의 카트리지에 충전되어 사용되는 흡연습관 교정기용 액상 조성물에 관한 것으로, 더욱 상세하게는 용매, 커피추출물, 비타민 혼합물, 향료, 향미제 및 코엔자임 Q10으로 이루어진다.
상기의 성분으로 이루어지는 흡연습관 교정기용 액상 조성물은 천연의 원료로 이루어지며, 발암물질이나 니코틴 성분이 함유되지 않고, 비타민 성분이 함유되어 있을 뿐만 아니라 구강 및 비강을 상쾌하게 하는 효과를 나타낸다.The present invention relates to a liquid composition for use in a smoking habit modifier filled in a cartridge of an electronic cigarette, more particularly, a solvent, a coffee extract, a vitamin mixture, a fragrance, a flavoring agent and a coenzyme Q 10 .
The liquid composition for a smoking habit modifier comprising the above components is made of a natural raw material and does not contain carcinogens or nicotine components and contains not only vitamin components but also refreshing mouth and nasal cavity.
Description
본 발명은 흡연습관 교정기용 액상 조성물에 관한 것으로, 더욱 상세하게는 천연의 원료로 이루어지며, 발암물질이나 니코틴 성분이 함유되지 않고, 비타민 성분이 함유되어 있을 뿐만 아니라 구강 및 비강을 상쾌하게 하는 효과를 나타내는 흡연습관 교정기용 액상 조성물에 관한 것이다.
The present invention relates to a liquid composition for a smoking habit correction device, and more particularly to a liquid composition for a smoking habit correction device, which is made of a natural raw material and contains no carcinogens or nicotine components and contains not only vitamin components but also oral and nasal The present invention relates to a liquid composition for a smoking habit correction device.
최근 국내외 적으로 흡연에 대한 규제가 강화되고 있으며, 흡연 과정에서 발생하는 포름알데히드, 아세트알데히드, 나프틸아민, 니켈, 벤젠, 비닐 클로라이드, 비소, 카드뮴, 벤조피렌 및 페놀 등과 같은 발암물질이나 인체 유해물질로 인해 흡연자의 건강이 위협받고 있으며, 간접흡연이나 구취유발 등과 같은 문제점이 발생하고 있다.Recently, regulations on smoking have been strengthened both domestically and abroad, and the regulation of smoking has been strengthened. Smoking and harmful substances such as formaldehyde, acetaldehyde, naphthylamine, nickel, benzene, vinyl chloride, arsenic, cadmium, The health of smokers is threatened, and problems such as secondhand smoke and bad breath are caused.
상기의 문제점을 해소하기 위해 흡연습관을 줄여주거나 금연에 도움을 주는 전자담배의 사용량이 증가하고 있는데, 종래에 전자담배는 니코틴 액상 또는 담배향 액상을 수증기로 만들어 담배를 피는 효과를 발생하기 위한 것으로, 전자담배는 담배연기를 흡입하는 흡입부, 액상이 저장되는 저장부(카트리지 포함), 액상을 발열수단에 의해 기화시키는 기화부, 전원을 공급하는 배터리로 구성된다.In order to solve the above problems, the amount of e-cigarettes to reduce smoking habit or to help quit smoking has been increasing. In the past, electronic cigarettes have been used to generate the effects of smoking cigarettes by using water vapor as a nicotine liquid or tobacco- The electronic cigarette includes a suction unit for sucking cigarette smoke, a storage unit (including a cartridge) for storing a liquid phase, a vaporizer for vaporizing the liquid phase by a heating means, and a battery for supplying power.
즉, 사용자가 흡입을 시작하면 저장부에 수용된 니코틴 액상 또는 담배향 액상을 기화부에 포함된 기화기로 보내고, 전원공급부로부터 전원을 인가받은 기화기에서 액상이 기화되도록 열을 발생시켜 수증기 형태의 담배연기를 분무할 수 있도록 이루어지며, 기존의 담배와 달리 인체에 유해한 물질이 제거된 순수한 니코틴만을 흡입할 수 있기 때문에 금연 보조 도구로 주로 사용되고 있다.That is, when the user starts sucking, the nicotine liquid or the cigarette liquor liquid contained in the storage unit is sent to the vaporizer included in the vaporizing unit, and heat is generated so that the liquid phase is vaporized in the vaporizer supplied with power from the power supply unit, And it is mainly used as a smoking cessation aid tool because it can inhale only pure nicotine which is harmful to the human body unlike the conventional cigarette.
그러나, 니코틴은 장기간 흡수하게 되면 초기엔 두통, 오심, 구토, 설사, 시력장애, 혈액 순환 부전, 심장마비, 혼수 및 경련 등과 같은 부작용이 발생할 수 있으며, 장기간 흡수하게 되면 만성적인 인후염, 만성 기관지염뿐만 아니라 심계항진, 부정맥, 혈압 상승, 협심증 등의 심장 및 혈관 증세 외에 식욕부진, 소화 불량 등의 위장 증세, 불면, 편두통 및 시신경 장애 등과 같은 증상을 유발하는 문제점이 있었다.
However, long-term absorption of nicotine can cause side effects such as headache, nausea, vomiting, diarrhea, visual disturbances, blood circulation impairment, heart attack, coma and convulsions, and chronic side effects such as chronic sore throat and chronic bronchitis In addition to cardiac and vascular signs such as palpitations, arrhythmia, elevated blood pressure and angina, there are problems such as gastrointestinal symptoms such as poor appetite, indigestion, insomnia, migraine and optic nerve disorder.
본 발명의 목적은 천연의 원료로 이루어지며, 발암물질이나 니코틴 성분이 함유되지 않고, 비타민 성분이 함유되어 있을 뿐만 아니라 구강 및 비강을 상쾌하게 하는 효과를 나타내는 흡연습관 교정기용 액상 조성물을 제공하는 것이다.It is an object of the present invention to provide a liquid composition for a smoking habit correction apparatus which is made of a natural raw material and which does not contain a carcinogenic substance or a nicotine component but contains a vitamin component and also has an effect of refreshing oral cavity and nasal cavity .
본 발명의 다른 목적은 간접흡연의 위험성이 없고, 구취를 유발하지 않는 긴장완화 효과를 갖는 흡연습관 교정기용 액상 조성물을 제공하는 것이다.
It is another object of the present invention to provide a liquid composition for a smoking habit correction apparatus which has no danger of passive smoking and has a relaxation effect that does not cause bad breath.
본 발명의 목적은 용매, 커피추출물, 비타민 혼합물, 향료, 향미제 및 코엔자임 Q10으로 이루어지는 것을 특징으로 하는 흡연습관 교정기용 액상 조성물을 제공함에 의해 달성된다.The object of the present invention is achieved by providing a liquid composition for a smoking habit modifier characterized by comprising a solvent, a coffee extract, a vitamin mixture, a flavor, a flavoring agent and coenzyme Q 10 .
본 발명의 바람직한 특징에 따르면, 상기 흡연습관 교정기용 액상 조성물은 용매 100 중량부, 커피추출물 0.05 내지 0.15, 비타민 혼합물 1 내지 3 중량부, 향료 8 내지 12 중량부, 향미제 2 내지 4 중량부 및 코엔자임 Q10 0.5 내지 1.5 중량부로 이루어지는 것으로 한다.According to a preferred feature of the present invention, the liquid composition for smoking habit adjuster comprises 100 parts by weight of solvent, 0.05 to 0.15 of coffee extract, 1 to 3 parts by weight of vitamin mixture, 8 to 12 parts by weight of fragrance, 2 to 4 parts by weight of flavor, Coenzyme Q 10 0.5 to 1.5 parts by weight.
본 발명의 더 바람직한 특징에 따르면, 상기 용매는 프로필렌글리콜 100 중량부, 글리세롤 50 내지 60 중량부 및 증류수 2 내지 4 중량부로 이루어지는 것으로 한다.According to a more preferred feature of the present invention, the solvent comprises 100 parts by weight of propylene glycol, 50 to 60 parts by weight of glycerol, and 2 to 4 parts by weight of distilled water.
본 발명의 더욱 바람직한 특징에 따르면, 상기 비타민 혼합물은 비타민 A, 비타민 B, 비타민 C 및 비타민 E로 이루어지는 것으로 한다.According to a further preferred feature of the present invention, the vitamin mixture is composed of vitamin A, vitamin B, vitamin C and vitamin E.
본 발명의 더욱 더 바람직한 특징에 따르면, 상기 향료는 멘솔 100 중량부, 페퍼민트 90 내지 110 중량부, 2,3,5-트리메틸피라진 15 내지 20 중량부, 2,3,5,6-테트라메틸피라진 15 내지 20 중량부, 스피아민트 오일 30 내지 40 중량부 및 2-아세틸피라진 15 내지 20 중량부 및 1,8-시네올 60 내지 70 중량부로 이루어지는 것으로 한다.According to a further preferred feature of the present invention, the perfume comprises 100 parts by weight of menthol, 90 to 110 parts by weight of peppermint, 15 to 20 parts by weight of 2,3,5-trimethylpyrazine, 2,3,5,6-tetramethylpyrazine 15 to 20 parts by weight, spearmint oil 30 to 40 parts by weight, 2-acetylpyrazine 15 to 20 parts by weight and 1,8-cineol 60 to 70 parts by weight.
본 발명의 더욱 더 바람직한 특징에 따르면, 상기 향미제는 에틸말톨로 이루어지는 것으로 한다.
According to a further preferred feature of the present invention, the flavor agent is made of ethyl maltol.
본 발명에 따른 흡연습관 교정기용 액상 조성물은 천연의 원료로 이루어지며, 발암물질이나 니코틴 성분이 함유되지 않아 인체에 무해하며, 비타민 성분이 함유되어 인체에 유익하고, 구강 및 비강을 상쾌하게 하는 탁월한 효과를 나타낸다.The liquid composition for smoking habit adjusters according to the present invention is made of natural raw materials and is harmless to the human body because it does not contain carcinogens or nicotine components and is beneficial to the human body by containing vitamin components and excellent in refreshing mouth and nasal cavity Effect.
또한, 간접흡연의 위험성이 없고, 구취를 유발하지 않는 탁월한 효과를 나타낸다.
In addition, there is no risk of secondhand smoke, and an excellent effect that does not cause bad breath is exhibited.
이하에는, 본 발명의 바람직한 실시예와 각 성분의 물성을 상세하게 설명하되, 이는 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 발명을 용이하게 실시할 수 있을 정도로 상세하게 설명하기 위한 것이지, 이로 인해 본 발명의 기술적인 사상 및 범주가 한정되는 것을 의미하지는 않는다.
Hereinafter, preferred embodiments of the present invention and physical properties of the respective components will be described in detail with reference to the accompanying drawings. However, the present invention is not limited thereto, And this does not mean that the technical idea and scope of the present invention are limited.
본 발명에 따른 흡연습관 교정기용 액상 조성물은 용매, 커피추출물, 비타민 혼합물, 향료, 향미제 및 코엔자임 Q10으로 이루어지며, 용매 100 중량부, 커피추출물 0.05 내지 0.15, 비타민 혼합물 1 내지 3 중량부, 향료 8 내지 12 중량부, 향미제 2 내지 4 중량부 및 코엔자임 Q10 0.5 내지 1.5 중량부로 이루어지는 것이 바람직하다.
The liquid composition for a smoking habit adjuster according to the present invention is composed of a solvent, a coffee extract, a vitamin mixture, a flavor, a flavoring agent and coenzyme Q 10 , and comprises 100 parts by weight of a solvent, 0.05 to 0.15 of a coffee extract, 1 to 3 parts by weight of a vitamin mixture, be made of parts of perfume from 8 to 12 parts by weight, a flavoring agent from 2 to 4 parts by weight of coenzyme Q 10 0.5 to 1.5 by weight.
상기 용매는 본 발명에 따른 흡연습관 교정기용 액상 조성물의 주재료로 흡연습관 교정기용 액상 조성물을 구성하는 각 성분이 고르게 혼합되도록 하는 역할을 하며, 프로필렌글리콜 100 중량부, 글리세롤 50 내지 60 중량부 및 증류수 2 내지 4 중량부로 이루어진다.The solvent is used as a main component of the liquid composition for a smoking habit modifier according to the present invention. The solvent mixes 100 parts by weight of propylene glycol, 50 to 60 parts by weight of glycerol, 2 to 4 parts by weight.
상기 프로필렌글리콜은 본 발명에 따른 흡연습관 교정기용 액상 조성물에 함유된 향료의 향을 잡아주며, 액상의 흐름성을 증가시켜 필터로 침투되는 속도를 증가시키는 역할을 한다.The propylene glycol serves to enhance the perfume contained in the liquid composition for smoking habit modifier according to the present invention and to increase the flow rate of the liquid phase to increase the rate of penetration into the filter.
또한, 상기 글리세롤은 본 발명에 따른 흡연습관 교정기용 액상 조성물의 맛을 증진시키는 역할을 하는데, 주로 혀 부분으로 느낄 수 있는 단맛을 증진시키는 역할을 한다.
In addition, the glycerol serves to enhance the taste of the liquid composition for a smoking habit modifier according to the present invention, and plays a role of promoting sweetness which can be felt mainly in the tongue portion.
상기 커피추출물은 0.05 내지 0.15 중량부가 함유되며, 커피원두를 열수 추출하여 제조되는데, 더욱 상세하게는 정제수 100 중량부에 커피원두 분쇄물 5 내지 10 중량부를 혼합하고 90 내지 100℃의 온도에서 5 내지 10분 동안 가열하여 제조된다.The coffee extract is prepared by hot water extraction of coffee bean, and more specifically, 5 to 10 parts by weight of ground coffee beans are mixed with 100 parts by weight of purified water. Lt; / RTI > for 10 minutes.
상기의 과정을 통해 제조되는 커피추출물은 본 발명에 따른 흡연습관 교정기용 액상 조성물에 우수한 향을 부여할 뿐만 아니라, 항산화 및 항암효과가 우수한 폴리레놀이 함유되어 있어 체내에 생리활성을 증진시키는 효과를 나타낸다.The coffee extract prepared through the above process not only imparts an excellent fragrance to the liquid composition for a smoking habit modifier according to the present invention but also contains a polyrenol having excellent antioxidant and anti-cancer effects, thereby enhancing the physiological activity in the body .
상기 커피추출물의 함량이 0.05 중량부 미만이면 상기의 효과가 미미하며, 상기 커피추출물의 함량이 0.15 중량부를 초과하게 되면 상기의 효과는 크게 향상되지 않으면서 제조비용을 증가시키게 된다.
If the content of the coffee extract is less than 0.05 parts by weight, the above effect is insignificant. If the content of the coffee extract is more than 0.15 parts by weight, the effect is not greatly improved but the manufacturing cost is increased.
상기 비타민 혼합물은 1 내지 3 중량부가 함유되며, 비타민 A, 비타민 B, 비타민 C 및 비타민 E로 이루어지는데, 비타민 A, 비타민 B, 비타민 C 및 비타민 E가 1:1:1:1의 중량부로 혼합되어 이루어지는 것이 바람직하다.1 to 3 parts by weight of vitamin A, vitamin B, vitamin C and vitamin E is mixed with 1: 1: 1: 1 parts by weight of vitamin A, vitamin B, vitamin C and vitamin E. .
상기 비타민 A는 시각, 성장, 세포분열 및 증식, 생식과 면역체계의 보존에 매우 중요한 역할을 하는 영양소로, 동물성 식품에서 얻어지는 레티노이드(retinoids)와 식물성 식품에서 공급되는 카로티노이드(carotenoids)로 구분되는데, 특히 녹황색채소에 많이 함유되어 있는 베타카로틴(β-carotene)은 체내에서 비타민A로 전환되며, 이는 영양학적으로 중요한 의미를 갖는다.The vitamin A is a nutrient that plays a very important role in vision, growth, cell division and proliferation, reproduction and preservation of the immune system. It is divided into retinoids obtained from animal foods and carotenoids supplied from plant foods, Beta-carotene (β-carotene), which is especially found in greenish-yellow vegetables, is converted into vitamin A in the body, which is nutritionally important.
또한, 상기 비타민 A는 세균감염에 대한 저항력강화, 피부와 점막의 보호, 야맹증, 약시예방, 항암효과, 고환과 난소의 기능강화, 피부모발, 치아, 성장 분화 촉진, 상피조직의 분화, 정상상태 조직 구성 및 시각망막 색조층 형성 등의 효능을 나타낸다.In addition, the above-mentioned vitamin A can be used as an antioxidant for the prevention and treatment of diseases such as strengthening of resistance against bacterial infection, protection of skin and mucous membranes, night blindness, prevention of amblyopia, anticancer effect, enhancement of testis and ovary, skin hair, Tissue structure and visual retina color layer formation.
또한, 상기 비타민 B는 티아민의 조효소 형태인 TPP(thiamin pyrophosphate)는 탄수화물 대사를 비롯한 에너지 대사에 참여하며, Na+ channel의 성분으로 신경전도에도 참여한다.In addition, vitamin B is a coenzyme form of thiamine TPP (thiamin pyrophosphate) participates in energy metabolism including carbohydrate metabolism, and participates in nerve conduction as a component of Na + channel.
상기 비타민 B는 만성변비 개선, 신경염 및 각기병 치료, 납중독에서 신체 보호, 피로물질 제거, 근무력증의 예방, 신경세포막을 정상 유지 및 위산 생성을 돕는 효능을 나타낸다.The above-mentioned vitamin B has the effect of improving chronic constipation, treating neuritis and otic disease, protecting the body from lead poisoning, removing fatigue substances, preventing myasthenia, maintaining the nerve cell membranes, and producing gastric acid.
또한, 상기 비타민 C는 오랫동안 배에서 생활하는 선원들이 괴혈병(Scurvy)이 생겼는데, 오렌지를 먹고 치료했다고 해서 아스코르빈산(ascorbic acid)이라고도 하며, 1928년에 동물의 부신과 오렌지에서 비타민C가 분리된 것을 기반으로 다양한 분야에 사용되고 있는데, 암과 바이러스간염의 치료보조, 감기, 헤르페스 등 모든 바이러스질환의 치료보조, 인터페론의 생산을 촉진, 감마글로불린의 생산을 촉진, 부신피질호르몬, 콜라겐의 합성보조, 혈중 콜레스테롤 수치를 낮추고, 발암물질인 니트로사민의 합성억제 및 카드뮴의 독성을 중화는 효능을 나타낸다.In addition, the above-mentioned vitamin C is called "ascorbic acid" because the crew living on the ship for a long time has a scurvy, and it is also called ascorbic acid. In 1928, vitamin C was separated from the adrenal gland of an animal and orange It has been used in various fields based on what has been used in the treatment of cancer and viral hepatitis, aids in the treatment of all viral diseases such as colds and herpes, promotes the production of interferon, promotes the production of gamma globulin, assists synthesis of collagen corticosteroids , Lowers blood cholesterol levels, inhibits the synthesis of nitrosamine, a carcinogen, and neutralizes the toxicity of cadmium.
또한, 상기 비타민 E는 1922년에, 사육되는 쥐가 식물유에 있는 어떤 물질을 식이에 같이 사용했을 때만 건강한 새끼를 낳는다는 사실을 발견하고 그 식물유 중의 성분을 비타민 E라고 명명한 것에서 유래되었으며, 이 물질은 1936년에 소맥배아유에서 단리되었으며, 1938년에 이 물질을 그리스어로 자식, 후손(tocos)이라는 뜻으로 토코페롤이라 부르게 되었다. 다른 지용성 비타민은 간에 저장되는 것과 달리 비타민E는 지방조직에 저장되며 인체에서 강력한 항산화작용으로 암을 예방하고 생식기능을 돕고 유산과 불임을 치료한다.α,β,γ,δ,θ 5종류가 있으며 열과 산에는 안전하고 알칼리에는 불안하다. 물에 녹지 않으므로 요리시에 손실은 없으나 산패된 지방이나 철분과 접촉하면 파괴되는데, 혈류촉진작용, 혈전방지, 콜레스테롤치 저하, 성기능과 운동기능 및 심장기능강화, 항산화작용으로 동맥경화와 암 및 노화의 원인물질 억제, 세포막의 산화지질 생성억제, 호르몬 분비 정상화 및 항산화작용으로 대기오염으로부터 폐점막을 보호하는 효능을 나타낸다.In addition, the vitamin E was derived from the fact that in 1922, when a ruminant was born with a healthy baby only when a substance in the vegetable oil was used together in the diet, the vitamin E was named as vitamin E, The material was isolated from wheat germ oil in 1936, and in 1938 it was called tocopherol in Greek, child, tocos. Other fat soluble vitamins are stored in adipose tissue, whereas vitamin E is stored in the liver. The strong antioxidant action in the body prevents cancer, helps reproductive function, and treats abortion and infertility. 5 kinds of α, β, γ, It is safe in heat and acid and unstable in alkali. Because it does not dissolve in water, there is no loss in cooking, but when it comes into contact with rancid fat or iron, it is destroyed. It prevents blood flow, prevents thrombosis, lowers cholesterol, strengthens sexual function and heart function, , Suppression of lipid peroxidation of cell membranes, normalization of hormone secretion, and antioxidant activity.
상기의 성분으로 이루어지는 비타민 혼합물의 함량이 1 중량부 미만이면 상기의 효과가 미미하며, 상기 비타민 혼합물의 함량이 3 중량부를 초과하게 되면 상기의 효과는 크게 향상되지 않으면서 제조비용을 증가시키게 된다.
If the content of the vitamin mixture is less than 1 part by weight, the above effect is insignificant. If the content of the vitamin mixture exceeds 3 parts by weight, the effect is not greatly improved but the production cost is increased.
상기 향료는 8 내지 12 중량부가 함유되며, 멘솔 100 중량부, 페퍼민트 90 내지 110 중량부, 2,3,5-트리메틸피라진 15 내지 20 중량부, 2,3,5,6-테트라메틸피라진 15 내지 20 중량부, 스피아민트 오일 30 내지 40 중량부 및 2-아세틸피라진 15 내지 20 중량부 및 1,8-시네올 60 내지 70 중량부로 이루어지는데, 본 발명에 따른 흡연습관 교정기용 액상 조성물에 향을 부여할 뿐만 아니라, 구강 및 비강을 상쾌하게 하는 효과를 나타낸다.8 to 12 parts by weight of the perfume are contained, and 100 parts by weight of menthol, 90 to 110 parts by weight of peppermint, 15 to 20 parts by weight of 2,3,5-trimethylpyrazine, 15 to 20 parts by weight of 2,3,5,6-tetramethylpyrazine, 20 to 40 parts by weight of spearmint oil, 15 to 20 parts by weight of 2-acetylpyrazine and 60 to 70 parts by weight of 1,8-cineol. In the liquid composition for smoking habit adjuster according to the present invention, fragrance But also shows an effect of refreshing the oral cavity and nasal cavity.
상기 멘솔은 박하의 잎이나 줄기를 수증기로 증류하여 얻어지는 것으로, 상쾌한 청량감의 느낌을 부여하는 역할을 하고, 상기 페퍼민트는 신경을 안정시키고 집중력을 증가시키는 효과를 나타내며, 상기 2,3,5-트리메틸피라진과 상기 2,3,5,6-테트라메틸피라진은 향을 부여하며, 상기 스피아민트 오일은 구강 및 비강에 청량감을 부여하고, 상기 2-아세틸피라진은 달콤한 향을 부여하며, 상기 시네올은 신경을 안정시키는 효과를 나타낸다.The menthol is obtained by distilling the leaves or stems of the peppermint with water vapor. The peppermint serves to give a refreshing feeling of coolness. The peppermint exhibits an effect of stabilizing the nerves and increasing the concentration, and the 2,3,5-trimethyl The pyrazine and the 2,3,5,6-tetramethylpyrazine give an aroma, the spearmint oil gives a refreshing sensation to the oral cavity and the nasal cavity, the 2-acetylpyrazine imparts a sweet aroma, It shows the effect of stabilizing the nerve.
상기의 성분으로 이루어지는 향료의 함량이 8 중량부 미만이면 상기의 효과가 미미하며, 상기 향료의 함량이 12 중량부를 초과하게 되면 상기의 효과는 크게 향상되지 않으면서 상대적으로 다른 성분들의 함량이 줄어들어 흡연습관 교정기용 액상 조성물의 기능성이 저하될 수 있다.
When the content of the fragrant ingredient is less than 8 parts by weight, the above effect is insignificant. When the content of the fragrance ingredient exceeds 12 parts by weight, the effect is not greatly improved but the content of the other ingredients is decreased, The functionality of the liquid composition for the habit correcting device may be lowered.
상기 향미제는 2 내지 4 중량부가 함유되며, 에틸말톨로 이루어지는데, 본 발명에 다른 흡연습관 교정기용 액상 조성물의 맛을 증진시키는 역할을 하는데, 주로 후각부분으로 느낄 수 있는 단맛을 증진시키는 역할을 한다.The flavoring agent is contained in an amount of 2 to 4 parts by weight, and is composed of ethyl maltol. The flavor enhancing taste of the liquid composition for smoking habit adjusters according to the present invention plays a role of promoting the sweet taste, do.
상기 향미제의 함량이 2 중량부 미만이면 상기의 효과가 미미하며, 상기 향미제의 함량이 4 중량부를 초과하게 되면 상기의 효과는 크게 향상되지 않으면서 제조비용을 증가시키게 된다.
If the content of the flavoring agent is less than 2 parts by weight, the above effect is insignificant. If the content of the flavoring agent exceeds 4 parts by weight, the effect is not greatly improved but the manufacturing cost is increased.
상기 코엔자임 Q10은 0.5 내지 1.5 중량부가 함유되며, 강력한 항산화제로 인체를 구성하고 있는 각 세포의 미토콘드리아에서 ATP의 생성을 촉진함으로써 에너지를 생성하도록 하는 역할을 하며, 이 외에도 심장기능강화, 잇몸병 치료 및 면역력 증진 등의 효과를 나타낸다.The coenzyme Q 10 is contained in 0.5 to 1.5 parts by weight. It acts as a strong antioxidant to generate energy by promoting the production of ATP in the mitochondria of each cell constituting the human body. In addition, And immunity enhancement.
상기 코엔자임 Q10의 함량이 0.5 중량부 미만이면 상기의 효과가 미미하며, 상기 코엔자임 Q10의 함량이 1.5 중량부를 초과하게 되면 상기의 효과는 크게 향상되지 않으면서 제조비용을 증가시키게 된다.
If the content of coenzyme Q 10 is less than 0.5 parts by weight, the above effect is insignificant. If the content of coenzyme Q 10 exceeds 1.5 parts by weight, the effect is not greatly improved but the manufacturing cost is increased.
따라서, 상기의 성분으로 이루어지는 흡연습관 교정기용 액상 조성물은 천연의 원료로 이루어지며, 발암물질이나 니코틴 성분이 함유되지 않아 인체에 무해하며, 비타민 성분이 함유되어 인체에 유익하고, 구강 및 비강을 상쾌하게 할 뿐만 아니라, 간접흡연의 위험성이 없고, 구취를 유발하지 않는 효과를 나타낸다.Therefore, the liquid composition for a smoking habit modifier comprising the above components is made of a natural raw material and is harmless to the human body because it does not contain a carcinogenic substance or a nicotine ingredient. It is beneficial to the human body by containing a vitamin component, In addition, there is no danger of passive smoking and the effect of not causing bad breath is exhibited.
Claims (6)
Wherein the liquid composition comprises a solvent, a coffee extract, a vitamin mixture, a flavor, and a flavor coenzyme Q 10 .
상기 흡연습관 교정기용 액상 조성물은 용매 100 중량부, 커피추출물 0.05 내지 0.15, 비타민 혼합물 1 내지 3 중량부, 향료 8 내지 12 중량부 및 향미제 2 내지 4 중량부 및 코엔자임 Q10 0.5 내지 1.5 중량부로 이루어지는 것을 특징으로 하는 흡연습관 교정기용 액상 조성물.
The method according to claim 1,
Wherein the liquid composition for smoking habit adjusters comprises 100 parts by weight of solvent, 0.05 to 0.15 parts of coffee extract, 1 to 3 parts by weight of a vitamin mixture, 8 to 12 parts by weight of fragrance, 2 to 4 parts by weight of flavor and 0.5 to 1.5 parts by weight of coenzyme Q 10 And the liquid composition for smoking habit adjuster is characterized in that the liquid composition for smoking habit correction is obtained.
상기 용매는 프로필렌글리콜 100 중량부, 글리세롤 50 내지 60 중량부 및 증류수 2 내지 4 중량부로 이루어지는 것을 특징으로 하는 흡연습관 교정기용 액상 조성물.
The method according to claim 1 or 2,
Wherein the solvent comprises 100 parts by weight of propylene glycol, 50 to 60 parts by weight of glycerol, and 2 to 4 parts by weight of distilled water.
상기 비타민 혼합물은 비타민 A, 비타민 B, 비타민 C 및 비타민 E로 이루어지는 것을 특징으로 하는 흡연습관 교정기용 액상 조성물.
The method according to claim 1 or 2,
Wherein the vitamin mixture is composed of vitamin A, vitamin B, vitamin C, and vitamin E.
상기 향료는 멘솔 100 중량부, 페퍼민트 90 내지 110 중량부, 2,3,5-트리메틸피라진 15 내지 20 중량부, 2,3,5,6-테트라메틸피라진 15 내지 20 중량부, 스피아민트 오일 30 내지 40 중량부 및 2-아세틸피라진 15 내지 20 중량부 및 1,8-시네올 60 내지 70 중량부로 이루어지는 것을 특징으로 하는 흡연습관 교정기용 액상 조성물.
The method according to claim 1 or 2,
The perfume comprises 100 parts by weight of menthol, 90 to 110 parts by weight of peppermint, 15 to 20 parts by weight of 2,3,5-trimethylpyrazine, 15 to 20 parts by weight of 2,3,5,6-tetramethylpyrazine, To 40 parts by weight of 2-acetylpyrazine, 15 to 20 parts by weight of 2-acetylpyrazine and 60 to 70 parts by weight of 1,8-cineol.
상기 향미제는 에틸말톨로 이루어지는 것을 특징으로 하는 흡연습관 교정기용 액상 조성물.The method according to claim 1 or 2,
Wherein the flavoring agent is ethyl maltol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150055413A KR20160124569A (en) | 2015-04-20 | 2015-04-20 | Liquid phase composition for smoking habit helping apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150055413A KR20160124569A (en) | 2015-04-20 | 2015-04-20 | Liquid phase composition for smoking habit helping apparatus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160124569A true KR20160124569A (en) | 2016-10-28 |
Family
ID=57244799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150055413A Abandoned KR20160124569A (en) | 2015-04-20 | 2015-04-20 | Liquid phase composition for smoking habit helping apparatus |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160124569A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107125803A (en) * | 2017-05-10 | 2017-09-05 | 深圳瀚星翔科技有限公司 | A kind of electronic cigarette tobacco tar and preparation method thereof |
| KR20190044987A (en) | 2017-10-23 | 2019-05-02 | 대구대학교 산학협력단 | Pharmaceutical composition for use in preventing or treating osteoporosis containing trimethylpyrazine as an active ingredient |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101208473B1 (en) | 2011-07-25 | 2012-12-05 | 장남숙 | Composition of atomized solution for electronic cigarette |
| KR101442095B1 (en) | 2007-06-25 | 2014-09-18 | 카인드 컨슈머 리미티드 | An inhalable composition comprising nicotine |
-
2015
- 2015-04-20 KR KR1020150055413A patent/KR20160124569A/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101442095B1 (en) | 2007-06-25 | 2014-09-18 | 카인드 컨슈머 리미티드 | An inhalable composition comprising nicotine |
| KR101208473B1 (en) | 2011-07-25 | 2012-12-05 | 장남숙 | Composition of atomized solution for electronic cigarette |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107125803A (en) * | 2017-05-10 | 2017-09-05 | 深圳瀚星翔科技有限公司 | A kind of electronic cigarette tobacco tar and preparation method thereof |
| KR20190044987A (en) | 2017-10-23 | 2019-05-02 | 대구대학교 산학협력단 | Pharmaceutical composition for use in preventing or treating osteoporosis containing trimethylpyrazine as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100370340B1 (en) | Tobacco Substitute Composition | |
| US7578299B2 (en) | Green tea-based substitute for cigarette and method for manufacturing the same | |
| CN112956729A (en) | Nicotine salt and preparation method thereof | |
| EP2941135A1 (en) | Tobacco substitute | |
| KR20180068236A (en) | Liquid composition for eletronic cigarette and manufacture method thereof | |
| JPH11137232A (en) | Herb product | |
| CN102771884A (en) | Tobacco juice of electronic cigarette having functions of antioxidation, softening blood vessels and refreshing breath | |
| KR20160124569A (en) | Liquid phase composition for smoking habit helping apparatus | |
| KR102013417B1 (en) | Composition for herbal cigarettes and manufacturing method threrof | |
| CN104026727B (en) | A kind of betel nut type chewing tobacco goods | |
| KR20160124572A (en) | Liquid phase composition for smoking habit helping apparatus having detoxifying nicotine | |
| CN105361237A (en) | Electronic cigarette tobacco juice with cholesterol reducing function and preparation method thereof | |
| KR20160124573A (en) | Liquid phase composition for smoking habit helping apparatus containing collagen | |
| CN103385538A (en) | A kind of corn chocolate cigarette and its preparation method | |
| GB2289204A (en) | A chewing gum for use as a nicotine substitute and slimming aid | |
| KR101193900B1 (en) | Liquid composition and the manufacturing method of electronic antismoking aid | |
| KR20160124570A (en) | Liquid phase composition for smoking habit helping apparatus having relaxation effect | |
| KR20160124571A (en) | Liquid phase composition for smoking habit helping apparatus having fatigue recovery | |
| CN113854621B (en) | Electronic atomized liquid with green tea taste and preparation method thereof | |
| EP2888951A1 (en) | Product comprising kratom | |
| KR102575957B1 (en) | Cigarette using kenaf and method for manufacturing the same | |
| KR101117971B1 (en) | Essence for electronic cigarette | |
| US2198188A (en) | Treating tobacco | |
| US20220061360A1 (en) | Health functional beverage | |
| CN113633014A (en) | Coffee-flavored refreshing electronic atomized liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20150420 |
|
| PA0201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20150911 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161019 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20170512 |
|
| PC1904 | Unpaid initial registration fee |